New Understanding Of Estrogen Benefit For Women: Lilly

8 September 1996

Researchers from Eli Lilly studying the mechanism of action of the investigational compound raloxifene have discovered a new pathway through which estrogen affects various organs, according to an article in the journal Science. Their findings may have important physiological implications for women, particularly their skeletal and cardiovascular health.

In a statement, Lilly notes that researchers have, for several decades, acknowledged the benefits of estrogen in protecting women from cardiovascular disease, osteoporosis and, more recently, Alzheimer's disease. However, they have also warned against the potential increase in breast and uterine cancer, and throughout this period have searched for an explanation of why estrogen affects various organs of the body so differently.

Raloxifene Studies In studies conducted with raloxifene, a drug that counters estrogen action in the breast while mimicking it in the bone, the Lilly team, led by molecular biologist Na Yang, has discovered a possible explanation of how the same drug may cause different effects, depending upon which tissue it is acting, and how the natural hormone itself manages to adopt so many different guises, according to Science.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight